A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India

• Principais autores: Raches Ella (Autor), Radhika Bobba (Autor), Sanjay Muralidhar (Autor), Sudhir Babji (Autor), Krishna Mohan Vadrevu (Autor), Maharaj Kishan Bhan (Autor)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2018-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: The World Health Organization recommends that rotavirus vaccines should be included in all national immunization programs. Some currently licensed oral rotavirus vaccines contain a buffering agent (either as part of a ready-to-use liquid formulation or added during reconstitution) to red...